Drug Profile
Research programme: lysosome pathway modulators - Astria Therapeutics
Alternative Names: CAT 5000Latest Information Update: 09 Sep 2021
Price :
$50
*
At a glance
- Originator Catabasis Pharmaceuticals
- Developer Astria Therapeutics
- Class
- Mechanism of Action Glutathione synthase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Metabolic disorders
Most Recent Events
- 08 Sep 2021 Catabasis Pharmaceuticals is now called Astria Therapeutics
- 04 Nov 2017 No recent reports of development identified for preclinical development in Metabolic-disorders in USA
- 07 May 2013 Programme is still in early research in US